Latest European Markets News

IODM Limited has broadened its revenue share agreement with TransferMate, now covering UK and European universities, aiming to deepen its presence in the higher education payments sector.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

Diamond Infraco has officially satisfied multiple regulatory conditions in its takeover offer for Atlas Arteria, freeing the offer from several major hurdles and holding a 34.56% stake.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

4DMedical launches the CLEAR clinical evidence program to accelerate adoption of its CT:VQ™ imaging technology in the US acute pulmonary embolism market, aiming to expand its addressable market to US$3 billion.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

OncoSil Medical has secured a pivotal ethics committee approval in Italy, reclassifying its OSPRItaly registry and enabling a streamlined procurement process that could double the number of authorised hospitals using its OncoSil™ device by mid-2027.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Energy One Limited reveals solid sales momentum and strategic AI integration under new CEO Ben Tranier, despite slight ARR timing delays and ongoing market complexity.